New Bioreactor Turns Stem Cells Into an Immune-Cell Factory, Producing 40 Million Human Macrophages Per Week Researchers at Hannover Medical School (MHH) have developed a bioreactor system capable of producing millions of human immune cells from induced pluripotent stem cells (iPS cells), marking a significant advancement in cell therapy manufacturing. The method, published in Nature Protocols, enables efficient, cost-effective, and scalable production of macrophages—key immune cells involved in pathogen defense, tissue repair, and disease research. Macrophages, often referred to as “scavenger cells,” play a central role in the human immune system. They are essential for defending against infections, clearing cellular debris, and supporting tissue regeneration. Beyond their natural functions, macrophages are already used in clinical applications, including the treatment of liver diseases, and are being investigated for use in infectious diseases, inflammation, fibrosis, cancer, and neurodegenerative conditions such as Alzheimer’s. They also serve as valuable tools for assessing drug purity, safety, and efficacy in preclinical testing. The MHH team’s bioreactor approach overcomes longstanding challenges in immune cell production. Previously, macrophages were generated either in small quantities for laboratory studies or through large-scale industrial processes that were often expensive and difficult to standardize. The new system uses medium-sized bioreactors to cultivate immune cells derived from iPS cells—somatic cells reprogrammed to a pluripotent state, capable of differentiating into any cell type in the body. This method supports research and therapeutic development by providing a reliable source of human macrophages for studying disease mechanisms and testing potential treatments. The bioreactors are designed to be efficient and user-friendly, reducing the technical barriers associated with immune cell manufacturing. By enabling consistent production of clinical-grade immune cells, the technology could accelerate the development of cell-based therapies and improve accessibility for future clinical applications. The function reflects a broader trend in bioreactor innovation for cell therapy manufacturing, where advances in automation, perfusion control, and scalable culture systems are addressing critical hurdles in producing therapeutic cells at scale. As the field progresses, such platforms may play a pivotal role in bringing stem cell-derived immune therapies from the laboratory to the clinic.
61